A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer

Full Title

A Phase I/II Study of VLS-1488 (An Oral KIF18A Inhibitor) in Subjects with Advanced Cancer

Purpose

Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).

This study is for people with these cancers:

  • Ovarian cancer
  • Ovarian and uterine carcinosarcomas
  • Uterine serous carcinoma
  • Squamous cell non-small cell lung cancer
  • Triple-negative breast cancer
  • Gastric (stomach) cancer
  • Esophageal cancer
  • Colorectal cancer
  • Bladder cancer
  • Head and neck cancer

Contact

For more information and to see if you can join this study, please call Dr. Claire Friedman’s office at 646-888-4593.

Protocol
23-329
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Chrisann Kyi
Co-Investigators
Alison Schram
Diseases
Colorectal Cancer › Colon Cancer
Colorectal Cancer › Rectal Cancer
Genitourinary Cancer › Bladder Cancer
Gynecologic Cancer › Ovarian Cancer
Head & Neck Cancer
Lung Cancer, Non-Small Cell › Other
Solid Tumors
Squamous Cell Carcinoma
Upper Gastrointestinal › Esophageal Cancer
Upper Gastrointestinal › Gastric Cancer
Uterine Sarcoma › Carcinosarcoma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT05902988
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description